BeOne Medicines (formerly BeiGene)

BeOne Medicines Ltd., formerly BeiGene, is a global oncology company. The legal entity completed its continuation from the Cayman Islands to Switzerland and changed its English name to BeOne Medicines Ltd. on May 27, 2025; its 2025 Form 10-K lists principal executive offices in Basel, Switzerland. [1] [2]

The company's history identifies John V. Oyler and Xiaodong Wang as the founders who launched the business in 2010. An earlier SEC filing describes the organization as having started as a Beijing research-and-development company and then developing significant commercial, manufacturing and research capabilities in China and the United States. BeOne's current corporate history presents that origin as the beginning of a global oncology platform. [3] [4]

The company's 2025 Form 10-K lists BRUKINSA (zanubrutinib), a BTK inhibitor, as approved in 77 markets with global commercial rights, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody, as approved in 51 markets with global rights. It also lists PARTRUVIX (pamiparib), sonrotoclax and other commercial or registration-stage products, alongside an oncology pipeline spanning hematologic malignancies and solid tumors. [1]

BeOne reports operations across six continents, more than 45 countries and regions with clinical trials planned or enrolled, more than 190 clinical trials initiated, approximately 12,000 employees and regulatory approvals for three internally developed medicines in more than 80 countries. Its relevance to this database also includes a collaboration with Amgen: the 2019 agreement covered commercialization of XGEVA, KYPROLIS and BLINCYTO in China and development and future China commercialization of up to 20 Amgen pipeline products. [5] [4]